

Distributing a metabolic pathway among a microbial consortium enhances production of natural products

Kang Zhou, Kangjian Qiao, Steven Edgar & Gregory Stephanopoulos

Metabolic engineering of microorganisms such as *Escherichia coli* and *Saccharomyces cerevisiae* to produce high-value natural metabolites is often done through functional reconstitution of long metabolic pathways. Problems arise when parts of pathways require specialized environments or compartments for optimal function. Here we solve this problem through co-culture of engineered organisms, each of which contains the part of the pathway that it is best suited to hosting. In one example, we divided the synthetic pathway for the acetylated diol paclitaxel precursor into two modules, expressed in either *S. cerevisiae* or *E. coli*, neither of which can produce the paclitaxel precursor on their own. Stable co-culture in the same bioreactor was achieved by designing a mutualistic relationship between the two species in which a metabolic intermediate produced by *E. coli* was used and functionalized by yeast. This synthetic consortium produced 33 mg/L oxygenated taxanes, including a monoacetylated dioxygenated taxane. The same method was also used to produce tanshinone precursors and functionalized sesquiterpenes.

Plants synthesize numerous structurally complex compounds that have important therapeutic properties^{1–6}, for example, paclitaxel (Abraxane), a potent antitumor agent¹. Heterologous production of these molecules in industrial microbes—mainly bacteria and yeasts—could provide a robust and sustainable production process. However, in bacteria it has been challenging to functionally express sophisticated eukaryotic enzymes that are often required in the synthesis of complex compounds⁷; on the other hand, it has been equally difficult to engineer yeasts for high-yield production of building blocks of natural products, such as the isoprenoid biosynthetic pathway of bacteria, which has higher theoretical yield than that of yeasts¹.

In nature, microbes can form interacting communities to accomplish chemically difficult tasks through division of labor among different species⁸. These natural microbial consortia have been used in food and other industries for decades⁹. Furthermore, researchers studied interactions of microbial species in mixed microbial cultures extensively in the 1960s and 1970s^{10,11}, aiming to establish operating diagrams for maintaining synthetic co-culture, which has been challenging owing to differences in their doubling time and secretion of toxic metabolites¹¹. Recently, there have been reports of production of biofuels and chemicals by a few synthetic consortia comprising genetically engineered microbes^{12–14}. However, those studies were mostly concerned with the stability of microbial consortia, whereas the more recent work focused on using nonconventional biomass such as cellulose^{12,13}. In these examples, which each involved two species, the first species provided only the carbon source for the second, which harbored the essential pathway for the final product in its entirety and was able to make the final product on its own. Strictly speaking, none of this prior work examined the potential to use more than one species for the purpose of

constructing a long synthetic pathway, which would enable production of structurally complex compounds.

In this study, we demonstrate the concept of reconstituting a heterologous metabolic pathway in a microbial partnership in which one microbe is engineered to synthesize a metabolic intermediate that is translocated to another microbe, in which it is further functionalized. In principle, it could be attractive to use synthetic microbial consortia for production of valuable metabolites, especially those with complex structures. One major advantage of this design is that each expression system and pathway module can be constructed and optimized in parallel, so that the time required for making the product would be substantially reduced. Other advantages of using synthetic consortia include, (i) taking advantage of unique properties and functions of different microbes, (ii) exploring beneficial interactions among consortium members to enhance productivity and (iii) minimizing problems arising from feedback inhibition by means of spatial pathway module segregation.

We report the use of two model laboratory and industrial microbes, *E. coli* and *S. cerevisiae* in a consortium to produce precursors of the anti-cancer drug paclitaxel. *E. coli* is a fast-growing bacterium that can be engineered to overproduce taxadiene, the scaffold molecule of paclitaxel¹. *S. cerevisiae*, having advanced protein expression machinery and abundant intracellular membranes, has been suggested as a preferable host for expressing cytochrome P450s (CYPs), which functionalize taxadiene by catalyzing multiple oxygenation reactions^{15–17}. We find that integration of parts of the whole pathway in separate species cultured together combines dual properties of rapid production of taxadiene in *E. coli* with efficient oxygenation of taxadiene by *S. cerevisiae*. This approach has overcome the challenges of using *E. coli* alone, in which fine-tuned taxadiene production was perturbed by introducing CYPs and functional expression of these enzymes in *E. coli*¹.

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Correspondence should be addressed to G.S. (gregstep@mit.edu).

Received 25 June 2014; accepted 10 November 2014; published online 5 January 2015; doi:10.1038/nbt.3095

RESULTS

Co-culture design to produce paclitaxel precursors

We first engineered *S. cerevisiae* BY4700 to express a cytochrome P450 taxadiene 5 α -hydroxylase (5 α CYP) and its reductase (CPR) (5 α CYP-CPR, fused as a single polypeptide; **Supplementary Fig. 1a**), which catalyze the first oxygenation reaction in the pathway of paclitaxel biosynthesis¹⁷. Taxadiene was efficiently oxygenated by this yeast (named TaxS1) when taxadiene was externally fed into the culture medium (**Supplementary Fig. 1b**), confirming that the 5 α CYP was functional in *S. cerevisiae* BY4700. Next, we co-cultured this 5 α CYP-CPR-expressing yeast with a taxadiene-producing *E. coli* (named TaxE1) in a fed-batch bioreactor with glucose as the sole carbon and energy source (**Fig. 1a**). The mixed culture produced 2 mg/L of oxygenated taxanes in 72 h (**Fig. 1b**), whereas in control experiments in which only *E. coli* TaxE1 (**Fig. 1b**) or *S. cerevisiae* TaxS1 (data not shown) was cultured, no oxygenated taxanes were produced. These results showed that taxadiene produced by *E. coli* diffused into *S. cerevisiae* and was subsequently oxygenated. However, the cell density of *E. coli* (**Fig. 1c**) and the total titer of taxanes (**Fig. 1d**) were substantially reduced in the presence of *S. cerevisiae* compared to the absence of yeast. The cause could be inhibition of *E. coli* by accumulated ethanol produced by yeast when grown on glucose (**Fig. 1e**). This hypothesis was validated by the fact that ethanol, at the highest concentration observed (50 g/L, **Fig. 1e**), completely inhibited *E. coli* cell growth and taxadiene production (**Supplementary Fig. 2**). Similar instances of inhibition have been observed before in natural systems when microbes compete for common resources¹⁸.

To overcome this problem, we designed a mutualistic interaction between the two microorganisms¹⁸. When *E. coli* metabolizes xylose it excretes acetate, which is inhibitory to its own growth¹⁹. *S. cerevisiae*, on the other hand, cannot metabolize xylose but can use acetate as the sole carbon source for growth without producing ethanol (**Fig. 2a** and **Supplementary Table 1**). We therefore switched the co-culture carbon source from glucose to xylose. Under these conditions *S. cerevisiae* grew in the xylose medium only in the presence of *E. coli* (**Fig. 2b**), and the concentration of extracellular acetate in the co-culture was considerably reduced compared with that observed when *E. coli* was grown on xylose on its own (**Fig. 2c**). More importantly, this stable co-culture minimized the ethanol concentration to below the limit of detection (0.1 g/L) throughout the experiment. In addition,

the titer of total taxanes produced by *E. coli* was not substantially affected by the presence of *S. cerevisiae* (**Fig. 2d**), suggesting that ethanol inhibition of *E. coli* was successfully eliminated, and taxadiene production proceeded unabated by the presence of yeast. However, although more oxygenated taxanes were produced in this co-culture (4 mg/L in 72 h, **Fig. 2e**) compared with the previous co-culture (2 mg/L in 72 h, **Fig. 1b**), the taxadiene oxygenation efficiency was still low (only 8% of total taxadiene produced, **Fig. 2**).

Optimization to improve taxadiene oxygenation

To increase taxadiene oxygenation, we first focused on optimizing the growth of *S. cerevisiae*, using the rationale that more yeast cells would express more 5 α CYP and therefore functionalize more taxadiene. We noted that acetate accumulated in the co-culture during the first 24 h (**Fig. 2c**), indicating that the initial yeast population was insufficient to convert all available substrate in the medium. This was corrected by increasing the initial inoculum of yeast and also periodically feeding additional carbon (xylose), nitrogen (ammonium) and phosphorous (phosphate) sources to ensure that these major nutrients were not limiting yeast growth. After these modifications, no acetate was detected throughout the entire fermentation, and the oxygenated taxane titer was improved about threefold (16 mg/L in 90 h, **Fig. 3a**). Under these conditions, as growth of *S. cerevisiae* was strictly limited by the amount of acetate secreted by *E. coli*, further increase of the relative amount of yeast in the culture relied on engineering the acetate pathway in *E. coli* (see below). We opted not to feed exogenous acetate in order to preserve the autonomous nature of the co-culture (**Supplementary Fig. 3**).

We next improved the specific oxygenation activity of yeast TaxS1. 5 α CYP-CPR (**Supplementary Fig. 1a**) was previously expressed under a strong constitutive promoter (TEFp in the co-culture above). We replaced TEFp by GPDp (a widely used strong promoter²⁰), UAS-GPDp (an enhanced version of GPDp²¹) and ACSp (promoter of acetyl-coA synthetase, a promoter from the acetate assimilation pathway^{22,23} that we hypothesized to be strong in our study as yeast TaxS1 grew on acetate) and tested taxadiene oxygenation efficiency by the corresponding strains. To this end, yeast strains (TaxS1, TaxS2, TaxS3 and TaxS4) were cultured without *E. coli* and the oxygenation rate of exogenously supplied taxadiene was measured (**Fig. 3b**). Based on the results of this assay, UAS-GPDp was selected as the




Figure 1 A competitive *E. coli*-*S. cerevisiae* consortium for production of oxygenated taxanes. **(a)** Both *E. coli* TaxE1 and the yeast TaxS1 grew on glucose; *E. coli* TaxE1 produces taxadiene which can diffuse to the yeast, where it is oxygenated. **(b)** Only the co-culture produces the oxygenated taxanes. **(c)** Growth of *E. coli* TaxE1 was inhibited by the presence of the yeast. **(d)** The taxane productivity of *E. coli* TaxE1 was compromised by the presence of the yeast. Total taxanes = taxadiene + oxygenated taxanes. **(e)** These inhibitions could be due to the ethanol produced by the yeast, which was confirmed by follow-up experiments (**Supplementary Fig. 2**). Error bars, mean \pm s.e.m. in all graphs (some error bars are smaller than the plot symbols). All replicates have also been plotted in all graphs (open circles), which indicates the number of replicates for each experiment. (For most points in **b,d,e**, there are two replicates for each time point; for points in **c**, there are at least three replicates.)




Figure 2 A mutualistic *E. coli*–*S. cerevisiae* consortium for production of oxygenated taxanes. **(a)** *E. coli* TaxE1 grows on xylose and produces acetate that serves as the sole carbon source for the yeast to grow. The taxadiene produced by *E. coli* TaxE1 is oxygenated in yeast TaxS1. **(b)** Yeast TaxS1 only grew in the presence of *E. coli* TaxE1. **(c)** Yeast TaxS1 removed the acetate produced by *E. coli* TaxE1. **(d)** The presence of yeast TaxS1 did not compromise taxane production of *E. coli* TaxE1. **(e)** Yeast TaxS1 only produces oxygenated taxanes when *E. coli* TaxE1 supplies taxadiene. The taxadiene oxygenation efficiency of this co-culture was 8% (4 mg/L out of 50 mg/L taxadiene was oxygenated). Error bars, mean \pm s.e.m. in all graphs (some error bars are smaller than the plot symbols). All replicates are plotted in all graphs (open circles). (For most points in **b–e**, there are two replicates for each time point.)

strongest promoter. Yeast strain TaxS4 was then co-cultured with *E. coli* TaxE1 using xylose as a substrate, and this co-culture produced significantly ($P < 0.01$) higher concentrations of oxygenated taxanes (25 mg/L in 90 h) compared with a co-culture in which the TEFp promoter was used (16 mg/L in 90 h, **Fig. 3c**). GPDp and ACSp were also tested in co-culture (**Fig. 3c**), and the results were fairly consistent with those of the feeding experiments (**Fig. 3b**), for example, ACSp, the promoter characterized to be weaker than TEFp in the feeding experiment, also led to lower production of oxygenated taxanes compared with TEFp in co-culture (**Fig. 3c**).

After increasing oxygenation efficiency in yeast, we engineered *E. coli* to overproduce acetate and thereby further potentially improve the growth rate of *S. cerevisiae* by increasing the concentration of available substrate. Production of acetate by *E. coli* is autoregulated; when acetate accumulates, *E. coli* growth is inhibited, resulting in a lower acetate production rate. First, we overexpressed the genes in the *E. coli* acetate production pathway (phosphate acetyltransferase, *pta*, and acetate kinase, *ackA*), but this increased neither the *S. cerevisiae* population density nor the oxygenation efficiency substantially (**Supplementary Fig. 4**). To overcome this problem, we inactivated oxidative phosphorylation by knocking out *atpFH*²⁴, which is the primary means of ATP production under aerobic conditions. The rationale for this modification was that the *atpFH* knockout would force *E. coli* to produce more acetate because acetate production would, under these conditions, become the primary ATP generation pathway (**Fig. 4a**). Indeed, this *E. coli* mutant (named TaxE4) produced up to 5.0 ± 0.1 g/L

acetate in test tubes, whereas the parental strain (*E. coli* TaxE1) produced only 2.3 ± 0.2 g/L acetate. The relative *S. cerevisiae* population was also much larger when yeast TaxS4 was co-cultured with *E. coli* TaxE4 compared to that with *E. coli* TaxE1 (**Fig. 4b**). More importantly, the titer of the oxygenated taxanes was further improved (33 mg/L in 120 h), and the percentage of the taxadiene oxygenated was significantly ($P < 0.01$) increased (up to 75%, **Fig. 4c**). Another strategy that could be tested in the future to further improve acetate production is the knockout of *E. coli* ACS, which assimilates extracellular acetate under certain conditions. Such a knockout might make more of the produced acetate available to the yeast strain.

Co-culture to produce monoacetylated dioxygenated taxane

We further engineered the co-culture to produce more complex paclitaxel precursors. A prevailing theory of paclitaxel early-synthesis suggests taxadien-5 α -ol is acetylated at its C-5 α position, followed by oxygenation at the C-10 β position¹⁵ (**Fig. 5a**). Because of the modular nature of our microbial consortium, the ability to functionalize taxadien-5 α -ol could be achieved by engineering of only the yeast module. Taxadien-5 α -ol acetyl-transferase (TAT²⁵) and taxane 10 β -hydroxylase (10 β CYP²⁶, fused with a CYP reductase¹) were co-expressed in yeast TaxS4. When the resulting yeast (named TaxS6) was co-cultured with *E. coli* TaxE4, the co-culture produced a monoacetylated dioxygenated taxane (molecular weight 346), which was identified as a single peak on the extracted ion chromatography (346 m/z, gas chromatography–mass spectrometry (GC-MS)) and was

Figure 3 Optimizing the yeast growth and engineering the yeast promoters improved production of the oxygenated taxanes. **(a)** Growth optimization (increasing the yeast inoculum and feeding additional nutrients) improved production of the oxygenated taxanes by more than twofold. **(b)** A stronger promoter (UAS-GPDp), compared to the previously used TEFp, was found by promoter screening. **(c)** The co-culture using UAS-GPDp also produced significantly ($P < 0.01$, based on Student's *t*-test) more oxygenated taxanes than that using TEFp. Error bars, mean \pm s.e.m. in all graphs (some error bars are smaller than the plot symbols). All replicates have also been plotted in all graphs (open circles). (For most points in **a** and **c**, there are two replicates for each time point; for points in **b**, there are at least three replicates.)





Figure 4 Inactivating oxidative phosphorylation in *E. coli* improved yeast growth and production of oxygenated taxanes. **(a)** Inactivation of oxidative phosphorylation forces the production of acetate, which then becomes the major pathway generating ATP in the *E. coli*. **(b)** The acetate-overproducing *E. coli* (TaxE4) improved for yeast growth in the co-culture. Control: TaxE1-TaxS4 co-culture; knockout: TaxE4-TaxS4 co-culture. **(c)** Taxadiene oxygenation efficiency was greatly improved when the *S. cerevisiae* was co-cultured with the acetate-overproducing *E. coli*. Oxygenation efficiency of the TaxE1-TaxS4 co-culture was ~50% (20 mg/L oxygenated taxanes per 40 mg/L total taxanes), and that of the TaxE4-TaxS4 co-culture was ~75% (30 mg/L oxygenated taxanes per 40 mg/L total taxanes). Error bars, mean \pm s.e.m. in all graphs (some error bars are smaller than the plot symbols). All replicates have also been plotted in all graphs (open circles, except **b**, in which $N = 4$). (For most points in **c**, there are two replicates for each time point; for **b**, there are at least three replicates.)



absent from the control co-culture not expressing the TAT and 10 β CYP (Fig. 5b). A ^{13}C labeling experiment confirmed that the oxygenated diol was indeed derived from taxadiene (Supplementary Fig. 5). The identified compound could be taxadien-5 α -acetate-10 β -ol, an important intermediate in the paclitaxel synthesis¹⁵, because its spectrum contained many of its fragment ions (346, 303, 286, 271 and 243 m/z ²⁷, Supplementary Fig. 5). To improve the titer and yield of this compound, we used a stronger promoter for expressing TAT (strain TaxS7), and the change of promoter improved the titer from 0.6 mg/L to 1 mg/L (Fig. 5c), confirming the hypothesis that this step was limiting. We then operated the bioreactor under a xylose-limited condition, which further increased the titer and also substantially improved the yield, by reducing the xylose consumption (from ~120 g/L to 80 g/L, Fig. 5c and Supplementary Fig. 6). To our knowledge, this is the first report of a monoacetylated, dioxygenated taxane being produced from a simple substrate (xylose) in microbes, and it reveals the usefulness of the modularity of a microbial partnership for synthesis of complex metabolites.

Production of other oxygenated isoprenoids by co-culture

The *E. coli*-*S. cerevisiae* co-culture developed in this study could be used for production of any compound if one of the pathway precursors can cross cell membranes. The method should be applicable to most isoprenoids, the largest class of natural products, because their scaffold molecules can generally permeate membranes. To test this hypoth-

esis, we examined the synthesis of another diterpene, ferruginol, the precursor of tanshinone, which is in clinical trials for treating heart disease^{28,29}. We replaced taxadiene synthase in *E. coli* TaxE4 with two enzymes (KSL and CPS, resulting in strain TaxE7) that are required for synthesizing miltiradiene²⁹, a membrane-crossing molecule. At the same time, in *S. cerevisiae* BY4700, we overexpressed a specific CYP and its reductase (SmCYP and SmCPR, resulting in strain TaxS8), which were reported to oxygenate miltiradiene into ferruginol²⁸ (Fig. 6a). When *E. coli* TaxE7 and yeast TaxS8 were co-cultured in the xylose medium, the co-culture successfully produced 18 mg/L ferruginol (Fig. 6b), which exceeds the highest titer reported in the literature (10 mg/L by *S. cerevisiae*²⁸). This shows that the co-culture concept is generally applicable to diterpenes, and demonstrates the advantages of co-culture over monoculture, that is, being able to construct parts of the pathway in parallel and achieve higher titers owing to microbial cooperation.

Finally, we synthesized a sesquiterpene—nootkatone, which is a high-end fragrance molecule³⁰. Similarly, we replaced the taxadiene synthase and geranylgeranyl diphosphate synthase in *E. coli* TaxE4 with a sesquiterpene synthase (VALC, resulting in strain TaxE8) to produce valencene, and in yeast BY4700, we overexpressed a specific CYP and its reductase (HmCYP and AtCPR, resulting in strain TaxS9) that can oxygenate valencene³⁰ (Fig. 6a). When these strains (TaxE8 and TaxS9) were co-cultured, they produced 30 mg/L nootkatol and a small quantity of nootkatone (0.8 mg/L, Fig. 6c). Recently,

Figure 5 Production of a monoacetylated dioxygenated taxane by the *E. coli*-*S. cerevisiae* co-culture. **(a)** Early paclitaxel biosynthetic pathway. **(b)** The yeast co-expressing 5 α CYP-CPR, TAT and 10 β CYP-CPR (TaxS6) produced putative taxadien-5 α -acetate-10 β -ol when co-cultured with a taxadiene-producing *E. coli*. Extracted ion chromatograms (346 m/z , molecular weight of monoacetylated dioxygenated taxane) are shown here. 5 α CYP: TaxE4/TaxS4 co-culture; 5 α CYP-TAT-10 β CYP: TaxE4/TaxS6 co-culture. **(c)** Using a stronger promoter (UASGPDp) to express TAT improved the titer of the monoacetylated dioxygenated taxane. Operating the bioreactor at a carbon-limited (CL) condition further improved the production titer and yield (xylose consumption was reduced by 30%). TEFp-TAT: TaxE4/TaxS6 co-culture, where expression of TAT was driven by TEFp; UASGPDp-TAT: TaxE4/TaxS7 co-culture, where UASGPDp was used to express TAT; UASGPDp-TAT CL: TaxE4/TaxS7 co-culture at a carbon limited condition. Error bars, mean \pm s.e.m. in all graphs (some error bars are smaller than the plot symbols). All replicates have also been plotted in all graphs (open circles). (For most points in **c**, there are two replicates for each time point.)





Figure 6 Use of the *E. coli*–*S. cerevisiae* co-culture for production of other oxygenated isoprenoids. (a) Illustration of biosynthetic pathways of ferruginol and nootkatone. (b) *E. coli* was engineered to produce miltiradiene from xylose (TaxE7), which cannot produce ferruginol on its own. When this *E. coli* strain was co-cultured with a yeast expressing a specific CYP and its reductase (TaxS8), the co-culture produced 18 mg/L ferruginol. Mass spectrum of the ferruginol was identical to the one in the literature (data not shown). (c) *E. coli* was engineered to produce valencene (TaxE8); by itself TaxE8 cannot produce oxygenated valencene. When the *E. coli* strain was co-cultured with a yeast expressing a specific CYP and its reductase (TaxS9), the co-culture produced 30 mg/L nootkatol and a low quantity of nootkatone. When an alcohol dehydrogenase was introduced to TaxS9, the resulting strain TaxS10 produced 4 mg/L nootkatone in the presence of TaxE8. Error bars, mean \pm s.e.m. in all graphs (some error bars are smaller than the plot symbols). All replicates have been plotted in all graphs (open circles). (For most points in b and c, there are two replicates for each time point.)



a *Pichia pastoris* alcohol dehydrogenase (PpADH3C) was shown to oxidize nootkatol in its native host³⁰. We introduced this enzyme to yeast TaxS9, yielding strain TaxS10, which upon co-culture with *E. coli* TaxE8, increased the nootkatone titer by a factor of 5 (4 mg/L, Fig. 6c). Again, these results supported the hypothesis that the co-culture concept should be widely applicable to production of oxygenated isoprenoids.

DISCUSSION

Our main motivation for using a stable co-culture was the introduction of modularity to the design of pathways for microbial metabolite production by assigning a different part of the metabolic pathway to each member of a partnership or synthetic consortium. In such an experimental set-up pathway modules can be separately optimized and assembled to enable optimal functioning of the complete pathway. The examples in this report demonstrate this modularity. The screening of a better promoter for CYP expression in yeast could be carried out independent of *E. coli* (Fig. 3), and producing the acetylated diol in the co-culture also required modification of only one of its modules (Fig. 5). Such modularity should substantially expedite the reconstruction of long biosynthetic pathways in microorganisms, as the construction of the cells carrying the pathway modules can be carried out in parallel, and the number of genetic modifications per cell is substantially reduced. To achieve this modularity, we ensured that the pathway modules in different cells did not directly interact with each other to minimize possible regulation. For example, CYPs and their reductases involved in taxane oxygenation generate reactive oxygen species^{31,32}, which inhibit two enzymes (ISPG and ISPH) in the taxadiene biosynthetic pathway containing iron-sulfur clusters that are hypersensitive to ROS³³. Spatial segregation, in two different microbes, of the pathway of taxadiene production from its oxygenation pathway prevents inactivation of ISPG/ISPH by ROS generated by CYPs.

Because of modularity of a co-culture approach, we were able to exploit advantages of the different species. Before this study, taxadiene could be overproduced only in *E. coli*¹, whereas most biochemical characterizations of the taxadiene-functionalizing enzymes were carried out in *S. cerevisiae*^{16,26,34}. By using *E. coli* to synthesize taxadiene and *S. cerevisiae* to functionalize it, we combined the advantages of the two

species for taxane production (fast growth of *E. coli* and complete protein expression system of *S. cerevisiae*). Using co-culture, we were able to synthesize a complex taxane (putative taxadiene-5 α -acetate-10 β -ol) (Fig. 5) that has never been produced by microorganisms growing on a simple carbon source, and to achieve higher titers of isoprenoid production than has been reported previously (Fig. 6b).

As most synthetic microbial consortia are competitive^{12,13} (Supplementary Fig. 7), a primary challenge in their design is to avoid the dominance of one species over another, due to a shorter doubling time^{11,12} or production of substances that are inhibitory to the other species¹³. Conventionally, titration of the inoculum ratio¹³ and optimization of growth conditions (such as pH and temperature¹¹) can be exploited to maintain coexistence. However, these strategies require time-consuming experimental trials or construction of sophisticated mathematical models¹³, whose parameters also need to be estimated experimentally. In addition, batch-to-batch variability can be high in these competitive co-cultures (data not shown). In this study, we avoided these complications by building a mutualistic co-culture in which *S. cerevisiae* used acetate as its sole carbon source, which was provided by, and inhibitory to, *E. coli*, which in turn grew better in the presence of yeast compared to without yeast (Supplementary Fig. 8). We applied additional genetic and growth constraints to enforce this cooperation, for instance, the respiration-deficient *E. coli* was forced to produce acetate as this was its primary way to generate cellular ATP (Fig. 4a), and the yeast also had to consume acetate because it cannot utilize xylose (Fig. 2a). Under such interdependency, the inoculum ratio of our co-culture can be simply set to overinoculation of yeast (the inoculum ratio of yeast to *E. coli* was ~40:1). This eliminated the inhibitory acetate levels but did not result in yeast overpopulation because yeast growth was strictly limited by the concentration of acetate produced by *E. coli*, leading to a balanced ratio of the two species (the ratio of yeast to *E. coli* was 1:2 at 41 h, Fig. 4b). Furthermore, this ratio was controllable through altering the specific acetate productivity (Fig. 4b). Because of this ability to alter the consortium composition by increasing the relative yeast population, we managed to minimize accumulation of the pathway intermediate (taxadiene) and increase the titer of oxygenated taxanes (Fig. 4c and Supplementary Fig. 9).

In addition to the mutualistic design, we also explored other strategies to avoid microbial competition. The first was a two-stage culture, in which *E. coli* was cultured separately for a few days before mixing with an active *S. cerevisiae* culture. This approach allowed both microbes to grow in their preferred conditions and taxadiene to be efficiently oxygenated (**Supplementary Fig. 10**). However, this process required a longer cultivation time (180 h) and, additionally, it was more complicated than that of the mutualistic co-culture. We also explored a two-carbon-source strategy, in which xylose can be used only by *E. coli*, and ethanol (manually added at low concentration, <2 g/L) was exclusively used by yeast (**Supplementary Fig. 11**). A stable co-culture could be maintained under these conditions by controlling the ethanol addition, and oxygenated taxanes were also produced at a relatively high titer (8 mg/L in 130 h, **Supplementary Fig. 12**). However, both *E. coli* and *S. cerevisiae* produced acetate under this scheme, leading to microbial inhibition (**Supplementary Fig. 12**), which was eliminated in the mutualistic design.

The co-culture concept is not restricted to pairing *E. coli* with *S. cerevisiae*. We have briefly explored the use of two different *E. coli* strains for production of oxygenated taxanes (**Supplementary Fig. 13**), which worked, although the titer was low, mainly owing to lack of the mutualistic interactions present in the *E. coli*–*S. cerevisiae* co-culture. As a general guideline, a target pathway should be divided into modules, each of which should be assigned to a specific host strain so that the combined genetic traits of the consortium strains are favorable for pathway completion. These microorganisms should rely on each other for supply of an essential nutrient or detoxification of an inhibitory substance, ensuring a stable and controllable microbial composition.

A necessary condition for co-culture is that the pathway intermediate (taxadiene) can cross cell membranes and is secreted to the extracellular medium. This property was first confirmed for taxadiene in prior studies where organic solvent mixed with *E. coli* cell culture was found to efficiently extract taxadiene (C20) from the cells in a bioreactor¹. We also measured distribution of taxadiene in *E. coli*, medium and yeast in this study, which confirmed that taxadiene can cross cell membranes efficiently even in the absence of an organic solvent (**Supplementary Fig. 14**). This physiochemical property is shared by many isoprenoids ranging from C5 to C40, including isoprene³⁵, limonene³, amorphadiene³⁶ and canthaxanthin³⁷. Hence, the co-culture concept should be generally applicable to the production of most isoprenoids (in this study, we have experimentally validated production of sesquiterpene and diterpene, **Fig. 6**).

The experiments reported here provide evidence that a secondary metabolite pathway can be reconstructed in a microbial consortium, paving the way for engineering the microbial synthesis of natural compounds with complex structures that currently cannot be efficiently synthesized in a single microbe such as alkaloids and flavonoids (including >10,000 molecules), which all derived from aromatic amino acids that can be produced in high titers, excreted by *E. coli*³⁸ and functionalized by *S. cerevisiae*³⁹. The co-culture can also benefit producing short-chain dicarboxylic acids (C6–C10), whose precursors are short-chain fatty acids that can be easily produced in engineered *E. coli*^{40,41} and efficiently oxidized in the yeast expressing CYPs⁴².

METHODS

Methods and any associated references are available in the [online version of the paper](#).

Note: Any Supplementary Information and Source Data files are available in the [online version of the paper](#).

ACKNOWLEDGMENTS

We acknowledge useful discussions and input from A. Ghaderi, F. Lam, H. Zhang, J. Avalos and W. Wang. This work was supported by National Institutes of Health grant 1-R01-GM085323-01A1 and the Singapore MIT Alliance.

AUTHOR CONTRIBUTIONS

K.Z. and G.S. conceived the project. K.Z., K.Q., S.E. and G.S. designed the experiments, analyzed the results and wrote the manuscript. K.Z., K.Q. and S.E. did all the experiments.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the [online version of the paper](#).

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Ajikumar, P.K. *et al.* Isoprenoid pathway optimization for Taxol precursor overproduction in *Escherichia coli*. *Science* **330**, 70–74 (2010).
- Paddon, C.J. *et al.* High-level semi-synthetic production of the potent antimalarial artemisinin. *Nature* **496**, 528–532 (2013).
- Alonso-Gutierrez, J. *et al.* Metabolic engineering of *Escherichia coli* for limonene and perillyl alcohol production. *Metab. Eng.* **19**, 33–41 (2013).
- Ajikumar, P.K. *et al.* Terpenoids: opportunities for biosynthesis of natural product drugs using engineered microorganisms. *Mol. Pharm.* **5**, 167–190 (2008).
- Hefferon, K. Plant-derived pharmaceuticals for the developing world. *Biotechnol. J.* **8**, 1193–1202 (2013).
- Melnik, S. & Stoger, E. Green factories for biopharmaceuticals. *Curr. Med. Chem.* **20**, 1038–1046 (2013).
- Chang, M.C., Eachus, R.A., Trieu, W., Ro, D.K. & Keasling, J.D. Engineering *Escherichia coli* for production of functionalized terpenoids using plant P450s. *Nat. Chem. Biol.* **3**, 274–277 (2007).
- Agapakis, C.M., Boyle, P.M. & Silver, P.A. Natural strategies for the spatial optimization of metabolism in synthetic biology. *Nat. Chem. Biol.* **8**, 527–535 (2012).
- Smid, E.J. & Lacroix, C. Microbe-microbe interactions in mixed culture food fermentations. *Curr. Opin. Biotechnol.* **24**, 148–154 (2013).
- Fredrickson, A.G. & Stephanopoulos, G. Microbial competition. *Science* **213**, 972–979 (1981).
- Davison, B.H. & Stephanopoulos, G. Effect of pH oscillations on a competing mixed culture. *Biotechnol. Bioeng.* **28**, 1127–1137 (1986).
- Bayer, T.S. *et al.* Synthesis of methyl halides from biomass using engineered microbes. *J. Am. Chem. Soc.* **131**, 6508–6515 (2009).
- Minty, J.J. *et al.* Design and characterization of synthetic fungal-bacterial consortia for direct production of isobutanol from cellulosic biomass. *Proc. Natl. Acad. Sci. USA* **110**, 14592–14597 (2013).
- Xia, T., Eiteman, M.A. & Altman, E. Simultaneous utilization of glucose, xylose and arabinose in the presence of acetate by a consortium of *Escherichia coli* strains. *Microb. Cell Fact.* **11**, 77 (2012).
- Guerra-Bubb, J., Croteau, R. & Williams, R.M. The early stages of taxol biosynthesis: an interim report on the synthesis and identification of early pathway metabolites. *Nat. Prod. Rep.* **29**, 683–696 (2012).
- Jennewein, S., Long, R.M., Williams, R.M. & Croteau, R. Cytochrome p450 taxadiene 5 α -hydroxylase, a mechanistically unusual monooxygenase catalyzing the first oxygenation step of taxol biosynthesis. *Chem. Biol.* **11**, 379–387 (2004).
- Hefner, J. *et al.* Cytochrome P450-catalyzed hydroxylation of taxa-4(5),11(12)-diene to taxa-4(20),11(12)-dien-5 α -ol: the first oxygenation step in taxol biosynthesis. *Chem. Biol.* **3**, 479–489 (1996).
- Nowak, M.A. Five rules for the evolution of cooperation. *Science* **314**, 1560–1563 (2006).
- Eiteman, M.A. & Altman, E. Overcoming acetate in *Escherichia coli* recombinant protein fermentations. *Trends Biotechnol.* **24**, 530–536 (2006).
- Sun, J. *et al.* Cloning and characterization of a panel of constitutive promoters for applications in pathway engineering in *Saccharomyces cerevisiae*. *Biotechnol. Bioeng.* **109**, 2082–2092 (2012).
- Blazek, J., Garg, R., Reed, B. & Alper, H.S. Controlling promoter strength and regulation in *Saccharomyces cerevisiae* using synthetic hybrid promoters. *Biotechnol. Bioeng.* **109**, 2884–2895 (2012).
- De Virgilio, C. *et al.* Cloning and disruption of a gene required for growth on acetate but not on ethanol: the acetyl-coenzyme A synthetase gene of *Saccharomyces cerevisiae*. *Yeast* **8**, 1043–1051 (1992).
- Kratzer, S. & Schuller, H.J. Transcriptional control of the yeast acetyl-CoA synthetase gene, ACS1, by the positive regulators CAT8 and ADR1 and the pleiotropic repressor UME6. *Mol. Microbiol.* **26**, 631–641 (1997).
- Causey, T.B., Zhou, S., Shanmugam, K.T. & Ingram, L.O. Engineering the metabolism of *Escherichia coli* W3110 for the conversion of sugar to redox-neutral and oxidized products: homoacetate production. *Proc. Natl. Acad. Sci. USA* **100**, 825–832 (2003).
- Walker, K., Schoendorf, A. & Croteau, R. Molecular cloning of a taxa-4(20), 11(12)-dien-5 α -ol-O-acetyl transferase cDNA from *Taxus* and functional expression in *Escherichia coli*. *Arch. Biochem. Biophys.* **374**, 371–380 (2000).

26. Schoendorf, A., Rithner, C.D., Williams, R.M. & Croteau, R.B. Molecular cloning of a cytochrome P450 taxane 10 beta-hydroxylase cDNA from *Taxus* and functional expression in yeast. *Proc. Natl. Acad. Sci. USA* **98**, 1501–1506 (2001).
27. Wheeler, A.L. *et al.* Taxol biosynthesis: differential transformations of taxadien-5 alpha-ol and its acetate ester by cytochrome P450 hydroxylases from *Taxus* suspension cells. *Arch. Biochem. Biophys.* **390**, 265–278 (2001).
28. Guo, J. *et al.* CYP76AH1 catalyzes turnover of miltiradiene in tanshinones biosynthesis and enables heterologous production of ferruginol in yeasts. *Proc. Natl. Acad. Sci. USA* **110**, 12108–12113 (2013).
29. Zhou, Y.J. *et al.* Modular pathway engineering of diterpenoid synthases and the mevalonic acid pathway for miltiradiene production. *J. Am. Chem. Soc.* **134**, 3234–3241 (2012).
30. Hom, E.F. & Murray, A.W. Niche engineering demonstrates a latent capacity for fungal-algal mutualism. *Science* **345**, 94–98 (2014).
31. Pillai, V.C., Snyder, R.O., Gumaste, U., Thekkumkara, T.J. & Mehvar, R. Effects of transient overexpression or knockdown of cytochrome P450 reductase on reactive oxygen species generation and hypoxia reoxygenation injury in liver cells. *Clin. Exp. Pharmacol. Physiol.* **38**, 846–853 (2011).
32. Reed, J.R., Cawley, G.F. & Backes, W.L. Inhibition of cytochrome P450 1A2-mediated metabolism and production of reactive oxygen species by heme oxygenase-1 in rat liver microsomes. *Drug Metab. Lett.* **5**, 6–16 (2011).
33. Artsatbanov, V.Y. *et al.* Influence of oxidative and nitrosative stress on accumulation of diphosphate intermediates of the non-mevalonate pathway of isoprenoid biosynthesis in corynebacteria and mycobacteria. *Biochemistry* **77**, 362–371 (2012).
34. Rontein, D. *et al.* CYP725A4 from yew catalyzes complex structural rearrangement of taxa-4(5),11(12)-diene into the cyclic ether 5(12)-oxa-3(11)-cyclotaxane. *J. Biol. Chem.* **283**, 6067–6075 (2008).
35. Xue, J. & Ahring, B.K. Enhancing isoprene production by genetic modification of the 1-deoxy-D-xylulose-5-phosphate pathway in *Bacillus subtilis*. *Appl. Environ. Microbiol.* **77**, 2399–2405 (2011).
36. Zhou, K., Zou, R., Zhang, C., Stephanopoulos, G. & Too, H.P. Optimization of amorphadiene synthesis in *Bacillus subtilis* via transcriptional, translational, and media modulation. *Biotechnol. Bioeng.* **110**, 2556–2561 (2013).
37. Doshi, R., Nguyen, T. & Chang, G. Transporter-mediated biofuel secretion. *Proc. Natl. Acad. Sci. USA* **110**, 7642–7647 (2013).
38. Santos, C.N., Xiao, W. & Stephanopoulos, G. Rational, combinatorial, and genomic approaches for engineering L-tyrosine production in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **109**, 13538–13543 (2012).
39. Minami, H. *et al.* Microbial production of plant benzyloquinoline alkaloids. *Proc. Natl. Acad. Sci. USA* **105**, 7393–7398 (2008).
40. Choi, Y.J. & Lee, S.Y. Microbial production of short-chain alkanes. *Nature* **502**, 571–574 (2013).
41. Leber, C. & Da Silva, N.A. Engineering of *Saccharomyces cerevisiae* for the synthesis of short chain fatty acids. *Biotechnol. Bioeng.* **111**, 347–358 (2014).
42. Craft, D.L., Madduri, K.M., Eshoo, M. & Wilson, C.R. Identification and characterization of the CYP52 family of *Candida tropicalis* ATCC 20336, important for the conversion of fatty acids and alkanes to alpha,omega-dicarboxylic acids. *Appl. Environ. Microbiol.* **69**, 5983–5991 (2003).

ONLINE METHODS

***E. coli* strains.** *E. coli* TaxE1 was previously constructed by Chin Giaw Lim (Manus Bio, Cambridge, Massachusetts, USA) in our laboratory. In brief, the MEP operon¹ (*dxs-idi-ispDF* controlled by T7 promoter) and the TG operon¹ (ts-ggpps controlled by T7 promoter) were integrated into locus *araA* and locus *lacY* of *E. coli* MG1655_Δ*recA*_Δ*endA*_Δ*DE3* (ref. 1), respectively. Strains used in this study are summarized in **Supplementary Table 2**.

To engineer *E. coli* TaxE1 to overproduce acetate, we overexpressed *pta* or *pta-ackA* operon by using a pSC101-based plasmid containing *trc* promoter (p5trc¹). *pta* or *ackA* amplified from *E. coli* MG1655 chromosome was assembled with part of p5trc by using the recently developed 'cross-lapping *in vitro* assembly' (CLIVA) method⁴³ (primer P1-P6 used), yielding plasmid p5trc-*pta* and p5trc-*ackA*, respectively. Primers used in this study are summarized in **Supplementary Table 3**. All the plasmids constructed in this study were validated by means of sequencing. Plasmid p5trc-*pta* was transformed into *E. coli* TaxE1, yielding *E. coli* TaxE2. *ackA* with *trc* promoter and terminator was amplified from p5trc-*ackA* and cloned into p5trc-*pta* using CLIVA (primer P7-P10 used), yielding plasmid p5trc-*pta-trc-ackA*. This plasmid was used to transform *E. coli* TaxE1, yielding *E. coli* TaxE3. After overexpression of *pta* and *pta-ackA*, we inactivated oxidative phosphorylation of *E. coli* TaxE1 by knocking out *atpFH* as described previously²⁴ (primer P11 and P12 used), yielding *E. coli* TaxE4.

To construct *E. coli* to produce miltiradiene, we knocked out *atpFH* of *E. coli* TaxE5 (a strain previously constructed by Chin Giaw Lim in our laboratory, as described previously²⁴) (primers P11 and P12 used), resulting in strain TaxE6. Then we transformed *E. coli* TaxE6 with plasmid p5T7-KSL-CPS-GGPPS, resulting in strain TaxE7. To obtain plasmid p5T7-KSL-CPS-GGPPS, we assembled KSL and CPS, amplified from synthetic DNA, with part of p5T7TG¹ via CLIVA (primers P13-P18 used). To construct *E. coli* to produce valencene, *ispA* amplified from *E. coli* genome and *valC* amplified from synthetic DNA were assembled with part of p5T7TG via CLIVA (primers P18-P23 used), yielding plasmid p5T7-ISP-VALC, which was used to transform into *E. coli* TaxE6, resulting in strain TaxE8.

To engineer *E. coli* to express taxadiene 5α-hydroxylase with its reductase (5αCYP-CPR, as a fusion protein), we transformed *E. coli* with plasmid p5trc-5αCYP-CPR MG1655_Δ*recA*_Δ*endA*_Δ*DE3*, yielding *E. coli* TaxE9. Plasmid p5trc-5αCYP-CPR was previously constructed by Chin Giaw Lim in our laboratory (unpublished works). To obtain this plasmid, we cloned the coding sequence of 5αCYP-CPR, amplified from p10At24T5αOH-tTCPR¹, into p5trc. To be compatible with *E. coli* TaxE9, we used *E. coli* EDE3Ch1TrcMEPp5T7TG¹ (named as TaxE10 in this study) to produce taxadiene in the *E. coli*-*E. coli* co-culture, as both strains were resistant to spectinomycin. An *E. coli* carrying unbalanced taxadiene synthetic pathway was also constructed in this study. We transformed *E. coli* with TaxE4 plasmid p5T7TG, resulting in strain TaxE11.

***S. cerevisiae* strains.** *S. cerevisiae* BY4700 (ATCC 200866, MATa *ura3Δ0*) was used to express the 5αCYP-CPR. Its coding sequence amplified from plasmid p10At24T5αOH-tTCPR¹ was cloned into plasmid p416-TEF (ATCC 87368) by using the restriction enzyme cloning (XbaI and HindIII, primers P24 and P25 used), yielding plasmid p416-TEFp-5αCYP-CPR. The auxotrophic marker and expression cassette of the new plasmid (URA-TEFp-5αCYP-CPR-CYC1t) was cloned via CLIVA into the integration shuttle vector pUC-YPRC15 (primer P26-P29 used), which was constructed by cloning a PCR fragment of the BY4700 YPRC locus into plasmid pUC19 (New England Biology) by means of restriction enzyme cloning (NotI and EcoRI, primer P30-P33 used). The resulting plasmid (pUC-YPRC15-URA-TEFp-17α5αCYP-CPR-CYCt) was linearized by using NotI and used to transform BY4700 (YPRC15 locus⁴⁴), yielding yeast TaxS1. This construction is illustrated in **Supplementary Figure 15**.

To replace the TEFp with GPDp and ACSp, GPDp amplified from plasmid p414-GPD (ATCC 87356) or ACSp amplified from BY4700 chromosome was combined with part of pUC-YPRC15-URA-TEFp-5αCYP-CPR via CLIVA (primer P34-P41 used), yielding plasmid pUC-YPRC15-URA-GPDp-5αCYP-CPR-CYCt and pUC-YPRC15-URA-ACSp-5αCYP-CPR-CYCt, respectively. These two plasmids were linearized by using NotI and used to transform BY4700 (YPRC15 locus), yielding yeast TaxS2 and TaxS3, respectively.

To add upstream activation sequence (UAS) to GPDp, the UAS_{TEF}-UAS_{CIT1}-UAS_{CLB2}²¹ was synthesized (as gblock gene fragment, Integrated DNA Technologies) and cloned into pUC-YPRC15-URA-GPDp-5αCYP-CPR-CYCt via CLIVA (primer P42-P45 used), yielding pUC-YPRC15-URA-UAS-GPDp-5αCYP-CPR-CYCt. This plasmid was linearized by using NotI and used to transform BY4700 (YPRC15 locus), yielding yeast TaxS4. Sequences of all the synthetic genes used in this study are summarized in **Supplementary Table 4**.

S. cerevisiae BY4719 (ATCC 200882, MATa *trp1Δ63 ura3Δ0*) was used to co-express 5αCYP-CPR, taxadien-5α-ol acetyl-transferase (TAT) and taxane 10β-hydroxylase with its reductase (10βCYP-CPR, as a fusion protein). Plasmid pUC-YPRC15-URA-GPDp-5αCYP-CPR-CYCt was linearized by using NotI and first transformed into BY4719 (YPRC15 locus), yielding yeast TaxS5. To further express TAT and 10βCYP-CPR in TaxS5, we constructed an integration vector (pUC-PDC6-TRP) that targeted locus PDC6 and contained TRP marker. First, plasmid pUC19 was combined with a PCR fragment of BY4700 PDC6 locus via CLIVA (primer P46-P49 used), yielding integration plasmid pUC-PDC6. The auxotrophic marker (TRP) of plasmid p414-GPD was then cloned into pUC-PDC6 via CLIVA (primer P50-P53 used), yielding integration plasmid pUC-PDC6-TRP. After the construction of the integration vector, the coding sequence of *Taxus cuspidata* TAT was synthesized (Genscript) and cloned into plasmid pJA115 (ref. 45) via CLIVA (primer P54-P57 used), yielding p426-TEFp-TAT-ACTt. The coding sequence of *Taxus cuspidata* 10βCYP was synthesized (as gblocks gene fragments, Integrated DNA Technologies) and cloned into pUC-YPRC15-URA-GPDp-5αCYP-CPR to replace the 5αCYP via CLIVA (primer P58-P63 used), yielding pUC-YPRC15-URA-GPDp-10βCYP-CPR-CYCt. The expression cassettes of these two plasmids (TEFp-TAT-ACTt and GPDp-10βCYP-CPR-CYCt) were assembled with part of the integration vector pUC-PDC6-TRP via CLIVA (primer P64-P69 used), yielding pUC-PDC6-TRP-(GPDp-10βCYP-CPR-CYCt)-(TEFp-TAT-ACTt). This plasmid was linearized by using NotI and transformed into TaxS5 (PDC6 locus⁴⁴), yielding yeast TaxS6.

To replace the promoter of TAT (TEFp) with a stronger promoter (UASGPDp), the coding sequence of TAT amplified from plasmid p426-TEFp-TAT-ACTt was assembled with part of pUC-YPRC15-URA-UAS-GPDp-5αCYP-CPR-CYCt via CLIVA (primer P59 and P70-72 used), resulting in plasmid pUC-YPRC15-URA-UAS-GPDp-TAT-CYCt; the coding sequence of 10βCYP-CPR amplified from pUC-YPRC15-URA-GPDp-10βCYP-CPR-CYCt was assembled with part of p426-TEFp-TAT-ACTt via CLIVA (primer P56, P57, P73 and P74 used), resulting in plasmid p426-TEFp-10βCYP-CPR-ACTt. Then the expression operon of plasmid pUC-YPRC15-URA-UAS-GPDp-TAT-CYCt and plasmid p426-TEFp-10βCYP-CPR-ACTt was assembled with part of integration plasmid pUC-PDC6-TRP via CLIVA (primer P65-P68, P75 and P76 used), resulting in plasmid pUC-PDC6-TRP-(TEFp-10βCYP-CPR-ACTt)-(UAS-GPDp-TAT-CYCt), which was linearized by NotI and transformed into TaxS5, resulting in strain TaxS7.

To construct the yeast that can oxygenate miltiradiene, the coding sequence of SmCYP-SmCPR was synthesized and assembled with part of plasmid pUC-YPRC15-URA-UAS-GPDp-5αCYP-CPR-CYCt via CLIVA (primer P77-P82 used), resulting in plasmid pUC-YPRC15-URA-UAS-GPDp-SmCYP-SmCPR-CYCt, which was used to transform *S. cerevisiae* BY4700, resulting in strain TaxS8. To construct the yeast that can produce nootkatone from valencene, the coding sequence of HmCYP-AtCPR was synthesized and assembled with part of plasmid pUC-YPRC15-URA-UAS-GPDp-5αCYP-CPR-CYCt via CLIVA (primer P81-P86 used), resulting in plasmid pUC-YPRC15-URA-UAS-GPDp-HmCYP-AtCPR-CYCt, which was linearized by NotI and transformed into *S. cerevisiae* BY4700, resulting in strain TaxS9. To improve the nootkatone production, the coding sequence of PpADHC3 was amplified from *Pichia pastoris* genomic DNA and assembled with part of plasmid p426-TEFp-TAT-ACTt via CLIVA (primer), resulting in plasmid p426-TEFp-PpADHC3-ACTt; the expression operon of this plasmid was further assembled with plasmid pUC-YPRC15-URA-UAS-GPDp-HmCYP-AtCPR-CYCt via CLIVA (primer P56, P57, P87 and P88 used), resulting in plasmid pUC-YPRC15-URA-(UAS-GPDp-HmCYP-AtCPR-CYCt)-(TEFp-PpADHC3-ACTt), which was linearized by NotI and transformed into *S. cerevisiae* BY4700, resulting in strain TaxS10.

Characterization of the yeast cultures by feeding taxadiene. All *S. cerevisiae* strains were characterized in the absence of *E. coli* before the co-culture experiment. We used 14-ml glass tubes (Pyrex) for this type of characterization. A colony of *S. cerevisiae* was inoculated into 1 ml YPD medium (10 g/L yeast extract, 20 g/L peptone, 20 g/L glucose) and grown at 30 °C/250 r.p.m. until cell density OD₆₀₀ reached 2. Then 10 µl of 6 g/L synthetic taxadiene stock solution (in DMSO) was added to start the experiments, and the cultures were incubated at 22 °C/250 r.p.m. The same procedure was used to compare yeast growth and activity when grown on glucose or acetate, except the medium was the one used in bioreactor experiments with indicated carbon source.

Bioreactor experiments for the *E. coli*–*S. cerevisiae* co-culture. A 1-liter Bioflo bioreactor (New Brunswick) was used for all the bioreactor works in this study. In initial experiments, seed cultures of *E. coli* and *S. cerevisiae* were inoculated into 500 ml of defined medium (13.3 g/L KH₂PO₄, 4 g/L (NH₄)₂HPO₄, 1.7 g/L citric acid, 0.0084 g/L EDTA, 0.0025 g/L CoCl₂, 0.015 g/L MnCl₂, 0.0015 g/L CuCl₂, 0.003 g/L H₃BO₃, 0.0025 g/L Na₂MoO₄, 0.008 g/L Zn(CH₃COO)₂, 0.06 g/L Fe(III) citrate, 0.0045 g/L thiamine, 1.3 g/L MgSO₄, pH 7.0) containing 5 g/L yeast extract and 40 g/L glucose (or 20 g/L xylose). To prepare a seed culture of *E. coli*, we inoculated a colony of the *E. coli* into Luria-Bertani (LB) medium (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, pH = 7) and grown at 37 °C/250 r.p.m. overnight. 5 ml of the grown cell suspension (OD of ~6) was inoculated into the bioreactor. To prepare a seed culture of *S. cerevisiae*, a colony of the *S. cerevisiae* was inoculated into YPD medium and grown at 30 °C/250 r.p.m. until cell density OD₆₀₀ reached 20. Then 10 ml of the grown cell suspension was centrifuged at 3,000g for 2 min, and pellets were resuspended in PBS and inoculated into the bioreactor. In the control experiments, only *E. coli* or *S. cerevisiae* was inoculated into the bioreactor. To improve growth of the microbes (refer to Fig. 3a), ammonium phosphate was co-fed with xylose (1 g (NH₄)₂HPO₄ per 5 g xylose) and more seed culture of the *S. cerevisiae* was inoculated (pellets of 50 ml of grown cell suspension, OD₆₀₀ = 20).

During the fermentation, oxygen was supplied by filtered air at 0.5 liter/min and agitation was adjusted to maintain dissolved oxygen levels at 30% (280–800 r.p.m.). The pH of the culture was controlled at 7.0 using 10% NaOH and 0.5 M HCl. The temperature of the culture in the bioreactor was controlled at 30 °C until the dissolved oxygen level dropped below 40%. The temperature of the bioreactor was then reduced to 22 °C and the *E. coli* was induced with 0.1 mM IPTG. During the course of the fermentation, the concentration of glucose (or xylose), acetate and ethanol was monitored at constant time intervals. As the glucose concentration dropped below 20 g/L, 20 g/L of glucose was introduced into the bioreactor. As the xylose concentration dropped below 10 g/L, 50 g/L of xylose was introduced into the bioreactor.

Bioreactor experiments for the *E. coli*–*E. coli* co-culture. A half-liter of rich medium (5 g/L yeast extract, 10 g/L tryptone, 10 g/L NaCl, 5 g/L K₂HPO₄, 8 g/L glycerol, pH7) containing 50 mg/L spectinomycin was inoculated with 5 ml of grown culture (OD of 4) of *E. coli* TaxE5 and 5 ml of grown culture (OD of 4) of *E. coli* TaxE6.

During the fermentation, oxygen was supplied by filtered air at 0.5 liter/min and agitation was adjusted to maintain dissolved oxygen levels at 30% (280–800 r.p.m.). The pH of the culture was controlled at 7.0 using 10% NaOH. The temperature of the culture in the bioreactor was controlled at 30 °C until the dissolved oxygen level dropped below 40%. The temperature of the bioreactor was then reduced to 22 °C and the *E. coli* was induced with 0.1 mM IPTG. During the course of the fermentation, the concentration of glycerol and acetate was monitored at constant time intervals. Glycerol was fed into the bioreactor at the rate of 0.65 g/h.

Test tube experiments for characterizing acetate production of *E. coli*. A colony of *E. coli* was inoculated into LB medium, and incubated at 37 °C/250 r.p.m. overnight. 10 µl of grown cells were inoculated into the same medium as the one used in *E. coli*–*S. cerevisiae* bioreactors. The cell suspension was incubated at 22 °C/250 r.p.m. for 96 h and samples were taken for extracellular acetate measurement.

Quantification of isoprenoids. At indicated time points, 200 µl of cell suspension was sampled and mixed with 200 µl ethyl acetate and 100 µl 0.5-mm glass beads. The mixture was vortexed at room temperature for 20 min, and clarified by centrifugation at 18,000g for 2 min. 1 µl of the ethyl acetate phase was analyzed by GC-MS (Varian saturn 3800 GC attached to a Varian 2000 MS). The samples were injected into a HP-5ms column (Agilent Technologies USA). Helium at flow rate 1.0 ml/min was used as the carrier gas. The oven temperature was kept at 100 °C for 1 min, then increased to 175 °C at an increment of 15 °C/min, then increased to 220 °C at an increment of 4 °C/min, then increased to 290 °C at an increment of 50 °C/min and finally held at this temperature for 1 min. The injector and transfer line temperatures were both set at 250 °C. The MS was operated under scan mode (40–400 *m/z*) and total ion count of taxanes was used for the quantification. Taxadiene, nootkatol and nootkatone were quantified by using the calibration curve (total ion count vs. concentration) constructed with authentic standard.

The 5αCYP was reported to produce multiple oxygenated taxanes in *S. cerevisiae*³⁴. After analyzing co-culture samples, we also observed many peaks on total ion chromatography (40–400 *m/z*, GC-MS) between 11–18.5 min, where we did not observe any peak when a sample of the single cultures was analyzed (Supplementary Fig. 16a). Five of the major peaks contained considerable amounts of 288 *m/z* signal (characteristic mass of mono-oxygenated taxane, 272 (taxadiene) + 16 (oxygen), Supplementary Fig. 16b). Among them, two were previously identified as oxa-cyclotaxane (OCT) and taxadien-5α-ol³⁴ (Supplementary Fig. 17), but the other three taxanes have not been identified before (Supplementary Fig. 18). As a conservative estimate, we only considered these five oxygenated taxanes for calculating titer of the total oxygenated taxanes. As standards of these five monooxygenated taxanes, the monoacetylated dioxygenated taxane and ferruginol were not available, they were quantified by using the taxadiene calibration curve.

Quantification of extracellular metabolites. At the indicated time points, 1.1 ml of cell suspension was sampled and centrifuged at 18,000g for 1 min. The supernatant was sterilized by using 0.2 µm filter. 1 ml of filtered supernatant was analyzed by high-performance liquid chromatography (Waters 2695 separation module coupled to Waters 410 differential refractometer) to measure concentration of extracellular glucose, xylose, acetate and ethanol. Bio-Rad HPX-87H column was used and 14 mM sulfuric acid was used as mobile phase at the flow rate of 0.7 ml/min.

Quantification of *E. coli* and *S. cerevisiae* cell number. To measure cell number of *E. coli* in the *E. coli*–*S. cerevisiae* co-cultures, 2 µl of cell suspension was diluted in 200 µl sterile PBS, and 2 µl of the diluted cell suspension was further diluted in 200 µl sterile PBS. 50 µl of the repeatedly diluted cell suspension was plated on LB agar plate (1.5% agar) and incubated at 37 °C for 20 h. After the incubation, only *E. coli* colonies were visible on the plate (the yeast colonies were only visible after at least 48 h at this condition). This method of measuring colony forming units was time consuming and low throughput. We later developed a sucrose gradient centrifugation method to quantify the cell number of both *E. coli* and *S. cerevisiae* in the co-culture. At indicated time points, 0.5 ml of cell suspension was sampled and loaded onto 1 ml of 45% sucrose solution in a 14-ml falcon tube, which was then centrifuged at 2,100g for 2 min. Microbes in the supernatant were exclusively *E. coli* and those in the pellets were mostly *S. cerevisiae* (Supplementary Fig. 19). After this separation, the cell number of the two microbes could be quantified by measuring optical density at 600 nm.

43. Zou, R., Zhou, K., Stephanopoulos, G. & Too, H.P. Combinatorial engineering of 1-deoxy-D-xylulose 5-phosphate pathway using cross-lapping *in vitro* assembly (CLIVA) method. *PLoS ONE* **8**, e79557 (2013).

44. Flagfeldt, D.B., Siewers, V., Huang, L. & Nielsen, J. Characterization of chromosomal integration sites for heterologous gene expression in *Saccharomyces cerevisiae*. *Yeast* **26**, 545–551 (2009).

45. Avalos, J.L., Fink, G.R. & Stephanopoulos, G. Compartmentalization of metabolic pathways in yeast mitochondria improves the production of branched-chain alcohols. *Nat. Biotechnol.* **31**, 335–341 (2013).